Global Diabetic Retinopathy Treatment Market – Industry Trends and Forecast to 2030

Diabetic Retinopathy Treatment Market Analysis and Size

Diabetes is a serious problem worldwide, where the inefficiency of the pancreas to produce insulin leads to an increase in blood glucose levels. Diabetic retinopathy is a result of diabetes causing retinal damage. The global prevalence of diabetic retinopathy was around 22.27% Globally, the incidence of DR in diabetic patients is projected to be 27.0%. The services launched to diagnose and improve the disease enhance the market growth in the country. Furthermore, there has been a huge demand for anti-VEGF drugs that has uplifted the market growth.

Data Bridge Market Research analyses that the diabetic retinopathy treatment market, which was USD 7.05 billion in 2022, would rise to USD 12.03 billion by 2030 and is expected to undergo a CAGR of 6.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Diabetic Retinopathy Treatment Market Scope and Segmentation

Market Definition

Diabetic retinopathy (DR) is the most common diabetic eye disease and is a top cause of blindness in people with diabetes. It is mainly caused by fluctuations in blood glucose levels leading to abnormal growth in the light-sensitive tissues present in the eye. When this fluid leaks, it causes the macula to swell or thicken, leading to vision loss. This disease is commonly witnessed in children aged 20 to 74 years.

Global Diabetic Retinopathy Treatment Market Dynamics

Drivers

• Increasing Collaborations Associated with Diabetic Retinopathy Treatment

Numerous collaborations are associated with diabetic retinopathy that leads to market growth. For Instance, Eyenuk, Inc, in collaboration with Discovery Health, has launched a new Diabetic Retinopathy Screening Benefit nationwide in South Africa, powered by the cutting-edge EyeArt Artificial Intelligent System in 2021. It helps in allowing the detection of the onset of diabetic retinopathy very quickly. This factor leads to the growth of the market.

• Increasing Prevalence of Diabetes

The growing burden of diabetes is boosting the growth of the market. According to "Diabetic retinopathy screening: a short guide," published by WHO in 2020, the incidence of any retinopathy in people with diabetes is 35%, whereas proliferative (vision-threatening) retinopathy is around 7%. Furthermore, the International Diabetes Federation Diabetes Atlas, 10th edition 2021, stated that in 2021, there would be about 536,600,000 people with diabetes globally, and it is expected to reach 783,700,000 by the year 2045. This increasing burden of diabetes surges the risk of diabetic retinopathy and is therefore anticipated to drive market growth. Thus, this factor help in the market growth.

Opportunities

• Growing Research Activities by Market Players

The increasing research and development activities for developing effective diagnostic and therapeutic methods for diabetic retinopathy will enhance segment growth. For instance, in "Mi-RNA-93 and Mi-RNA-152 in the Diagnosis of Type 2 Diabetes and Diabetic Retinopathy," published in 2022, MiR-93 and miR-152 can differentiate between patients who have diabetes and those with diabetic retinopathy. Both miRNAs can be potential biomarkers for diabetes and diabetic retinopathy, mainly for proliferative diabetic retinopathy. Thus, this factor boosts market growth.  

• Increasing Demand for Anti-VEGF Drugs

The increasing demand for anti-VEGF drugs is due to their efficiency and efficacy in treating diabetic retinopathy. The anti-VEGF drugs are commonly used to treat Proliferative Diabetic Retinopathy (PDR). Furthermore, these drugs were more beneficial than others, mainly in patients suffering from a vitreous hemorrhage, neovascular glaucoma, and before the vitrectomy procedure. Thus, this factor is a major factor that increases market growth.

Restraints/Challenges

• High Cost of Diabetic Retinopathy Treatment

The severe cost of treatment and diagnostic procedures associated with diabetic retinopathy hinders the market. Several procedures are costly and cannot be afforded by underdeveloped and developing countries. Thus, this factor impedes market growth.  

• Side Effects of Diabetic Retinopathy Treatment

There are several side effects that are associated with diabetic retinopathy treatment that causes market hindrance. There's also a risk of blood clots to form, which could cause heart attack or stroke. Other effects such as macular edema, visual field deficits, exudative retinal detachments, and night vision defects can be witnessed. Thus, this factor impede the market growth.

This diabetic retinopathy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic retinopathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2021, Eyenuk, Inc in collaboration with Discovery Health has launched a new Diabetic Retinopathy Screening Benefit in South Africa, which is powered by the cutting-edge EyeArt Artificial Intelligent System. It helps in allowing the detection of the onset of diabetic retinopathy rapidly.

Global Diabetic Retinopathy Treatment Market Scope

The diabetic retinopathy treatment market is segmented on the basis of treatment type, type, device type, severity, drug type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Laser Surgery
• Vitrectomy
• Intraocular Steroid Injection
• Anti-Vascular Endothelial Growth Factor Drug

Type

• Non-Proliferative
• Proliferative

Device Type

• Focal Laser Treatment
• Vitrectomy Devices
• Scatter Laser Treatment

Severity Type

• Mild
• Moderate
• Severe

Drug Type

• Aflibercept
• Bevacizumab
• Fluocinolone
• Ranibizumab
• Triamcinolone Acetonide Injection

End User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

Diabetic Retinopathy Treatment Market Regional Analysis/Insights

The diabetic retinopathy treatment market is analyzed and market size insights and trends are provided by treatment type, type, device type, severity, drug type, and end user as referenced above.

The countries covered in the diabetic retinopathy treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to grow during the forecast period diabetic retinopathy treatment market because of the well-established veterinary healthcare infrastructure in the region. Also, the wide presence of top porcine production countries, such as China, and a large meat-consuming population, are boosting the market growth.

North America dominates the market in the forecast due to the increasing market dominance of avastin, eylea, and lucentis, which are anti-VEGF drugs, and also the largest share due to the supportive reimbursement policies. Furthermore, the growing incidence of diabetes in this region also boosts the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The diabetic retinopathy treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for diabetic retinopathy treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the diabetic retinopathy treatment market. The data is available for historic period 2011-2021.

Competitive Landscape and Diabetic Retinopathy Treatment Market Share Analysis

The diabetic retinopathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetic retinopathy treatment market.

Some of the major players operating in the diabetic retinopathy treatment market are:

• Bayer AG (Germany)
• Aurobindo Pharma (India)
•  AbbVie Inc. (U.S.)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bausch Health Companies Inc. (U.S.)
• Accord Healthcare (U.K.)
• Genentech, Inc (U.S.).
• Regeneron Pharmaceuticals Inc (U.S.).
• Abbott (U.S.)
• Kowa Pharmaceuticals America, Inc. (U.S.).,
• Ampio Pharmaceuticals Inc. (U.S.).
• Lumenis Be Ltd (Israel)
• Alimera Sciences Europe Ltd (U.S.)
• Glycadia, Inc (U.S.)
• Oxurion NV (Belgium)

SKU-26599